- Home
- S vs APLS Comparison
S vs APLS Comparison
Compare S & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | S | APLS |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.2B |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | S | APLS |
|---|---|---|
| Price | $14.87 | $41.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 31 | 21 |
| Target Price | $19.28 | ★ $33.59 |
| AVG Volume (30 Days) | 9.3M | ★ 25.2M |
| Earning Date | 05-27-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.15 |
| Revenue | $1,001,278,000.00 | ★ $1,003,782,000.00 |
| Revenue This Year | $22.84 | N/A |
| Revenue Next Year | $17.32 | $18.19 |
| P/E Ratio | ★ N/A | $273.60 |
| Revenue Growth | 21.89 | ★ 28.46 |
| 52 Week Low | $11.81 | $16.83 |
| 52 Week High | $21.40 | $41.14 |
Technical Indicators
Market Signals| Indicator | S | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 84.57 |
| Support Level | $14.76 | $19.29 |
| Resistance Level | $14.98 | $41.14 |
| Average True Range (ATR) | 0.85 | 0.06 |
| MACD | -0.41 | -0.65 |
| Stochastic Oscillator | 1.64 | 58.33 |
Price Performance
Historical ComparisonAbout S SentinelOne Inc.
SentinelOne is a cloud-based cybersecurity company specializing in endpoint protection. SentinelOne's primary offering is its Singularity platform that offers a single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The California-based firm was founded in 2013 and went public in 2021.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).